GRNA Key Statistics, Chart & Performance
The current stock price of GRNA is 0.2995 USD. In the past month the price increased by 1.49%. In the past year, price decreased by -85.53%.
GRNA Latest News, Press Relases and Analysis
GRNA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 25 | 417.40B | ||
| AMGN | AMGEN INC | 15.43 | 181.72B | ||
| GILD | GILEAD SCIENCES INC | 15.46 | 157.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.58 | 109.42B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.79 | 80.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 855.65 | 57.20B | ||
| INSM | INSMED INC | N/A | 42.01B | ||
| NTRA | NATERA INC | N/A | 31.65B | ||
| BIIB | BIOGEN INC | 10.47 | 25.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.99 | 21.48B | ||
| INCY | INCYTE CORP | 15.9 | 19.93B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.10B |
Related stock screener links
About GRNA
Company Profile
GreenLight Biosciences Holdings PBC operates as a biotechnology company, which makes ribonucleic acid (RNA) products for human therapies and agriculture. The company is headquartered in Lexington, Massachusetts and currently employs 262 full-time employees. The company went IPO on 2021-01-14. The firm has a cell-free ribonucleic acid (RNA) production platform for the discovery, development, and commercialization of products to promote healthier plants, foods, and people. The firm's cell-free biomanufacturing platform enables the making of complex biological molecules-nucleic acids, peptides, carbohydrates, and many others using fermentation. Its technology platform provides integrated discovery, design, and development of RNA-based products used in advanced pharma discovery to agriculture and human health. The company has developed two manufacturing processes, one for plant health (dsRNA) and one for human health (mRNA) that both rely on synthesis of RNA from RNA building blocks, enzymes, and deoxyribonucleic acid (DNA) templates. The firm's plant program includes the Colorado Potato Beetle Program-Calantha; Varroa Mite Program, and Powdery Mildew Complex.
Company Info
GreenLight Biosciences Holdings PBC
29 Hartwell Avenue
Lexington MASSACHUSETTS US
Employees: 262
Phone: 16176168188.0
GreenLight Biosciences Holdings PBC / GRNA FAQ
What does GreenLight Biosciences Holdings PBC do?
GreenLight Biosciences Holdings PBC operates as a biotechnology company, which makes ribonucleic acid (RNA) products for human therapies and agriculture. The company is headquartered in Lexington, Massachusetts and currently employs 262 full-time employees. The company went IPO on 2021-01-14. The firm has a cell-free ribonucleic acid (RNA) production platform for the discovery, development, and commercialization of products to promote healthier plants, foods, and people. The firm's cell-free biomanufacturing platform enables the making of complex biological molecules-nucleic acids, peptides, carbohydrates, and many others using fermentation. Its technology platform provides integrated discovery, design, and development of RNA-based products used in advanced pharma discovery to agriculture and human health. The company has developed two manufacturing processes, one for plant health (dsRNA) and one for human health (mRNA) that both rely on synthesis of RNA from RNA building blocks, enzymes, and deoxyribonucleic acid (DNA) templates. The firm's plant program includes the Colorado Potato Beetle Program-Calantha; Varroa Mite Program, and Powdery Mildew Complex.
Can you provide the latest stock price for GreenLight Biosciences Holdings PBC?
The current stock price of GRNA is 0.2995 USD. The price decreased by -0.03% in the last trading session.
Does GreenLight Biosciences Holdings PBC pay dividends?
GRNA does not pay a dividend.
How is the ChartMill rating for GreenLight Biosciences Holdings PBC?
GRNA has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about GreenLight Biosciences Holdings PBC (GRNA) stock?
7 analysts have analysed GRNA and the average price target is 0.46 USD. This implies a price increase of 53.26% is expected in the next year compared to the current price of 0.2995.
How is the valuation of GreenLight Biosciences Holdings PBC (GRNA) based on its PE ratio?
GreenLight Biosciences Holdings PBC (GRNA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.14).
GRNA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to GRNA. When comparing the yearly performance of all stocks, GRNA is a bad performer in the overall market: 95.46% of all stocks are doing better.
GRNA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GRNA. Both the profitability and financial health of GRNA have multiple concerns.
GRNA Financial Highlights
Over the last trailing twelve months GRNA reported a non-GAAP Earnings per Share(EPS) of -1.14. The EPS decreased by -5.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.49 |
GRNA Forecast & Estimates
7 analysts have analysed GRNA and the average price target is 0.46 USD. This implies a price increase of 53.26% is expected in the next year compared to the current price of 0.2995.
For the next year, analysts expect an EPS growth of 26.28% and a revenue growth 167.93% for GRNA